Please login to the form below

Not currently logged in
Email:
Password:

Kisplyx

This page shows the latest Kisplyx news and features for those working in and with pharma, biotech and healthcare.

NICE gives green light to Ipsen's Cabometyx

NICE gives green light to Ipsen's Cabometyx

Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s

Latest news

  • Eisai wins EU licence for kidney cancer drug Kisplyx Eisai wins EU licence for kidney cancer drug Kisplyx

    Eisai wins EU licence for kidney cancer drug Kisplyx. Approved as a second-line combination treatment for advanced RCC. ... The European Commission has approved Kisplyx (lenvatinib) for the treatment of adults with advanced renal cell carcinoma (RCC)

  • HIV prevention pill heads July CHMP recommendations HIV prevention pill heads July CHMP recommendations

    HIV prevention pill heads July CHMP recommendations. Gilead’ s Truvada given positive opinion alongside Ipsen Pharma’ s Cabometyx and Eisai’ s Kisplyx. ... The panel also recommended approval of two targeted kidney cancer medicines - Ipsen Pharma's

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics